Risk assessment, prophylaxis, and monitoring measures for TLS 1

  • VENCLEXTATM can cause rapid reduction in tumor burden and poses a risk for TLS during the initial 5-week ramp-up phase
  • Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose and each dose increase

Assess TLS risk

Tumor lysis syndrome risk assessment image
  • Concomitant use of VENCLEXTA with strong or moderate CYP3A inhibitors or P-gp inhibitors increases venetoclax exposure, may increase the risk of TLS at initiation and during ramp-up phase, and may require VENCLEXTA dose adjustment (see Dose Modifications for Toxicities and Drug Interactions for dose modification information)